98%
921
2 minutes
20
Dual-atom catalysts (DACs) display excellent activity for the oxygen reduction reaction (ORR). The dual-metal configuration allows for synergistic interactions and tailored adsorption of key intermediates, thereby breaking traditional OH-OOH scaling relations and enabling dissociative O activation pathways. Recent studies suggest that the metal-metal (M-M) distance within DACs critically influences their electronic structure and catalytic behavior; however, a deep understanding of M-M distance effects on ORR thermodynamics and kinetics is presently lacking. Herein, density functional theory (DFT) calculations and microkinetic modeling are performed on 108 DACs with varied M-M distances (2.2-3.5 Å). Moderate M-M distances (≈3 Å) are found to weaken OH binding, lower the OH-OOH scaling slope, and promote bridging O adsorption for facile dissociation. The dissociative pathway lowered the effective scaling relation from ≈3.2 to 2.72 eV, approaching the theoretical value of 2.46 eV. Micro-kinetic simulations identified O activation as the rate-determining step during ORR, with DACs possessing a M-M distance ≈3 Å exhibiting the highest turnover frequencies, due the effective balancing of active-site availability and O activation efficiency. These findings highlight the key role of M-M distance in controlling ORR activity, guiding the design of next-generation DACs with improved efficiency.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/smll.202507733 | DOI Listing |
Eur Radiol
September 2025
Department of Radiology, Northeastern Ohio Medical University, Rootstown, OH, USA.
Objectives: Methods for measuring the ultrasound attenuation coefficient (AC) vary across different systems. Some have fixed regions of interest (ROI) while others have movable ROIs. Aims were to evaluate whether, using a system with a fixed ROI, correlation between AC and MRI proton density fat fraction (MRI-PDFF), and performance could be improved by (i) reducing fixed ROI length to 30 mm, changing starting point from the transducer, and (ii) using a movable ROI at different depths.
View Article and Find Full Text PDFJ Card Fail
August 2025
Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria. Electronic address:
Background: Introduction of disease-specific medication has revolutionized the management of transthyretin associated cardiomyopathy (ATTR-CM). However, dedicated trials included different patient populations, primary endpoints, and follow-up periods, rendering study comparison challenging. This systematic review and meta-analysis aimed to harmonize data from all phase-3 placebo-controlled drug trials in ATTR-CM to inform on the magnitude and timing of treatment efficacy of ATTR-specific medication.
View Article and Find Full Text PDFSmall
September 2025
School of Chemical Sciences, University of Auckland, Auckland, 1010, New Zealand.
Dual-atom catalysts (DACs) display excellent activity for the oxygen reduction reaction (ORR). The dual-metal configuration allows for synergistic interactions and tailored adsorption of key intermediates, thereby breaking traditional OH-OOH scaling relations and enabling dissociative O activation pathways. Recent studies suggest that the metal-metal (M-M) distance within DACs critically influences their electronic structure and catalytic behavior; however, a deep understanding of M-M distance effects on ORR thermodynamics and kinetics is presently lacking.
View Article and Find Full Text PDFJVS Vasc Sci
July 2025
Department of Physiology, College of Medicine, University of Kentucky, Lexington, KY.
Objective: In people with peripheral artery disease (PAD), the Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease (TELEX) randomized clinical trial tested whether telmisartan (TEL), with or without exercise, significantly improved 6-minute walk distance at 6-month follow-up, compared with placebo (PLA). This study investigated the effects of TEL on exploratory muscle biopsy outcomes of muscle cellular characteristics (myofiber size, satellite cell content, capillary density, extracellular matrix, and collagen area) and molecular characteristics (cell-specific transcriptomics) in people undergoing supervised exercise in the TELEX Trial.
Methods: Baseline and 6-month follow-up muscle biopsies were obtained from 13 participants with PAD in the TELEX trial randomized to exercise + TEL (n = 6) or exercise + PLA (n = 7).
J Neurol
August 2025
Friedrich-Baur-Institute, Department of Neurology, LMU Klinikum München, Munich, Germany.
Background And Objectives: In the COMET trial, avalglucosidase alfa treatment for late-onset Pompe disease was safe, tolerable and associated with stabilization or improvement in disease parameters through 97 weeks. We report outcomes in the trial extension through 145 weeks of treatment.
Methods: In this phase 3, double-blind, randomized trial, participants with previously untreated late-onset Pompe disease were randomly assigned to receive 20 mg/kg avalglucosidase alfa or alglucosidase alfa every other week for 49 weeks; thereafter, all patients received 20 mg/kg avalglucosidase alfa every other week.